Conferences

Conference data for April 13-14, 2021: AACR

April 20, 2021

New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting, including: Adagene, Antengene, Ascentage, Beigene, Eli Lilly, Innovent Biologics, Pharmabcine.

2021 China Pharmaceutical Innovation 100 Summit

Regulators need to up their game to support drugmakers’ global drug development, experts urge

April 13, 2021

By Elise Mak

No Comments

Speaking during the 2021 China Pharmaceutical Innovation 100 Summit, industry insiders called for more regulatory talent and even an organizational revamp to clear innovative products faster and support the global development strategies of Chinese drugmakers.

2021 China Pharmaceutical Innovation 100 Summit

China launches policies to encourage innovation, but pricing and payment remain pain points

April 13, 2021

By Elise Mak

No Comments

SHANGHAI – China’s regulatory environment has evolved to encourage drug innovation, but despite remarkable progress, mounting pricing pressure from the government and a weak insurance sector remain as barriers.

Conference data for April 13, 2021: AACR

April 13, 2021

No Comments

New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting, including: Gracell, Hummingbird.

Wuxi Healthcare Forum 2021

Asia’s digital capabilities benefit R&D and patients, but lacking harmonization hinders efficiency

March 16, 2021

By Elise Mak

No Comments

In the “The World for Asia, Asia for the World” panel discussion at the virtual Wuxi Healthcare Forum, investors and executives took note of the region’s digital capabilities for reducing R&D costs and timelines, while also calling for more harmonization on the regulatory front to empower R&D in Asia.

Conference data for Feb. 16, 2021: ASCO Genitourinary Cancers Symposium

Feb. 23, 2021

No Comments

New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology Genitourinary Cancers Symposium, including Astellas, Eisai, Merck, Seagen.

Conference data for Feb. 11, 2021: ASCO GU

Feb. 16, 2021

No Comments

Data presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium – Feb. 11-13, including Noxopharm.

WCLC 2021

KRAS drugs may do best in tough subtype

Feb. 9, 2021

By Anette Breindl

No Comments

KRAS is the most frequently mutated oncogene in solid tumors in general, and in lung tumors in particular. There are more patients whose lung tumors are driven by KRAS mutations than by ALK, Ros, Ret and TRK alterations. Combined. And after 40 years, they look to be getting a targeted therapy, or even two.

WCLC 2021: KRAS drugs may do best in tough subtype

Feb. 2, 2021

By Anette Breindl

No Comments

KRAS is the most frequently mutated oncogene in solid tumors in general, and in lung tumors in particular. There are more patients whose lung tumors are driven by KRAS mutations than by ALK, Ros, Ret and TRK alterations. Combined.

J.P. Morgan Healthcare Conference

Wanted: A sense of urgency, a roadmap and a global health system to battle future pandemics

Jan. 19, 2021

By Karen Carey

No Comments

As the world begins to emerge from a horrific pandemic, it has become abundantly clear that dangerous infections are here to stay, and it is up to health care leaders and citizens to remain prepared and vigilant in preventing another deadly and disruptive COVID-19.

Conferences, BioWorld Asia
RSS

Conference data for April 13-14, 2021: AACR

Regulators need to up their game to support drugmakers’ global drug development, experts urge

China launches policies to encourage innovation, but pricing and payment remain pain points

Conference data for April 13, 2021: AACR

Asia’s digital capabilities benefit R&D and patients, but lacking harmonization hinders efficiency

Conference data for Feb. 16, 2021: ASCO Genitourinary Cancers Symposium

Conference data for Feb. 11, 2021: ASCO GU

KRAS drugs may do best in tough subtype

WCLC 2021: KRAS drugs may do best in tough subtype

Wanted: A sense of urgency, a roadmap and a global health system to battle future pandemics

Free access to BioWorld coronavirus articles

Today's news in brief

Next up, Novavax, after April’s vaccine woes and therapeutic failures

Single dose of Pfizer vaccine not strong enough against variants, U.K. study shows

Split vote at adcom for avacopan; FDA not Hy on Chemocentryx trial setup

Conferences, BioWorld Asia RSS

Conferences, BioWorld Asia
RSS